Welcome to our dedicated page for Petvivo Holdings news (Ticker: PETVW), a resource for investors and traders seeking the latest updates and insights on Petvivo Holdings stock.
Petvivo Holdings, Inc. (PETVW) is a pioneer in developing innovative biomedical devices for companion animals, leveraging human medical advancements to address veterinary health challenges. This dedicated news hub provides investors and industry professionals with essential updates on the company's progress in pet therapeutics.
Access real-time announcements covering regulatory milestones, product developments, and strategic partnerships. Our curated collection includes earnings reports, technology licensing updates, and clinical trial progress related to PETVW's portfolio of joint care solutions like the Spryng™ OsteoCushion™ system.
Key updates focus on commercialization efforts for veterinary medical devices, intellectual property expansions, and market penetration strategies. Stay informed about PETVW's unique approach to adapting human biomaterials for animal health applications through this comprehensive news resource.
Bookmark this page for direct access to verified company communications and third-party analysis. Check regularly for developments in PETVW's mission to enhance animal mobility through advanced therapeutic solutions.
PetVivo Holdings, a biomedical device company focused on innovative therapeutics for pets, will present at the Aegis Capital Virtual Conference from May 2nd to 4th, 2023. CEO John Lai will discuss the company's Spryng product featuring OsteoCushion Technology, aimed at managing lameness and joint issues in companion animals.
Spryng is an injectable device that supports joint health by mimicking natural cartilage and is currently available for sale. The presentation is scheduled for May 3rd, 2023, from 12:25 PM to 12:55 PM ET. PetVivo holds a strong patent portfolio, with 17 products in development and a unique market strategy focused on veterinary devices.
PetVivo Holdings (NASDAQ: PETV, PETVW) has appointed Mary Grace Rutland as the new Business Development Manager for the Mid-Atlantic Region. Rutland, with 24 years of experience in animal health sales, will focus on promoting Spryng with OsteoCushion technology to veterinarians across the U.S. CEO John Lai expressed excitement about her addition, highlighting her previous roles in the industry, including positions at Fort Dodge Animal Health and Neogen Corporation. PetVivo specializes in innovative medical devices for companion animals, with Spryng aimed at treating lameness and joint-related conditions like osteoarthritis in dogs and horses. The company has a pipeline of 17 products and holds 19 patents covering its biomaterials and methods.
FAQ
What is the current stock price of Petvivo Holdings (PETVW)?
